GS0976 NCT02856555


Laboratory : GILEAD

Study Name : 

Phase 2

Study Number : NCT02856555

Number of patients recruited : 125

Probability to be under placebo : 33%

Contacts : 

Contact: Gilead Study Team

GS-US-426-3989@gilead.com







Share on StockTwits

WWW.NASHBIOTECHS.COM  -  Copyright G DIVRY 2015-2016